 Alexander Burnett
Concepts (194)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laparoscopy | 6 | 2023 | 188 | 1.960 |
Why?
| | Uterine Cervical Neoplasms | 12 | 2022 | 276 | 1.840 |
Why?
| | Endometrial Neoplasms | 7 | 2020 | 144 | 1.140 |
Why?
| | Obesity, Morbid | 2 | 2023 | 88 | 0.960 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2023 | 4 | 0.960 |
Why?
| | Gynecologic Surgical Procedures | 4 | 2009 | 31 | 0.920 |
Why?
| | Whole-Body Irradiation | 2 | 2014 | 160 | 0.890 |
Why?
| | Lymph Node Excision | 4 | 2011 | 140 | 0.730 |
Why?
| | Metformin | 2 | 2020 | 66 | 0.680 |
Why?
| | Hypoglycemic Agents | 2 | 2020 | 177 | 0.650 |
Why?
| | Interleukin-11 | 2 | 2013 | 9 | 0.560 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2016 | 644 | 0.520 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2014 | 21 | 0.500 |
Why?
| | Prescription Drugs | 1 | 2014 | 35 | 0.480 |
Why?
| | Hysterectomy | 4 | 2023 | 88 | 0.480 |
Why?
| | Uterine Neoplasms | 7 | 2007 | 63 | 0.480 |
Why?
| | Proton Pump Inhibitors | 1 | 2014 | 84 | 0.470 |
Why?
| | Radiation Tolerance | 1 | 2014 | 86 | 0.470 |
Why?
| | Robotics | 2 | 2010 | 45 | 0.430 |
Why?
| | Obesity | 2 | 2016 | 1202 | 0.430 |
Why?
| | Radiation-Protective Agents | 1 | 2013 | 116 | 0.420 |
Why?
| | Organotechnetium Compounds | 1 | 2011 | 8 | 0.400 |
Why?
| | Lymphedema | 1 | 2011 | 43 | 0.390 |
Why?
| | Vulvar Neoplasms | 1 | 2011 | 54 | 0.380 |
Why?
| | Lower Extremity | 1 | 2011 | 103 | 0.370 |
Why?
| | Radiopharmaceuticals | 1 | 2011 | 238 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2011 | 384 | 0.350 |
Why?
| | Female | 31 | 2023 | 28441 | 0.350 |
Why?
| | Cystadenocarcinoma, Papillary | 5 | 2006 | 15 | 0.340 |
Why?
| | Fertility | 2 | 2009 | 33 | 0.310 |
Why?
| | Vagina | 2 | 2023 | 47 | 0.300 |
Why?
| | Retrospective Studies | 5 | 2023 | 6432 | 0.300 |
Why?
| | Cervix Uteri | 1 | 2006 | 53 | 0.270 |
Why?
| | Humans | 33 | 2023 | 54284 | 0.270 |
Why?
| | Adenocarcinoma | 1 | 2009 | 428 | 0.260 |
Why?
| | Topotecan | 1 | 2005 | 19 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2005 | 106 | 0.240 |
Why?
| | Genital Neoplasms, Female | 1 | 2004 | 38 | 0.240 |
Why?
| | Postoperative Complications | 1 | 2011 | 1033 | 0.240 |
Why?
| | Ovarian Neoplasms | 4 | 2014 | 472 | 0.230 |
Why?
| | Adult | 18 | 2016 | 14207 | 0.230 |
Why?
| | Doxorubicin | 1 | 2005 | 259 | 0.230 |
Why?
| | Uterus | 1 | 2023 | 98 | 0.230 |
Why?
| | Lymph Nodes | 1 | 2004 | 284 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2007 | 1056 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2011 | 866 | 0.210 |
Why?
| | Middle Aged | 17 | 2020 | 13088 | 0.210 |
Why?
| | Aged | 15 | 2016 | 10054 | 0.210 |
Why?
| | Aged, 80 and over | 5 | 2016 | 3431 | 0.190 |
Why?
| | Intestines | 2 | 2013 | 204 | 0.170 |
Why?
| | Neoplasm Staging | 7 | 2006 | 806 | 0.170 |
Why?
| | Carcinoma | 2 | 2011 | 153 | 0.150 |
Why?
| | Dendritic Cells | 3 | 2014 | 142 | 0.150 |
Why?
| | Cell Proliferation | 2 | 2020 | 1096 | 0.150 |
Why?
| | Cancer Vaccines | 3 | 2014 | 103 | 0.150 |
Why?
| | Antineoplastic Agents | 2 | 2007 | 1300 | 0.150 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2020 | 40 | 0.140 |
Why?
| | Cystadenocarcinoma, Serous | 3 | 2005 | 74 | 0.140 |
Why?
| | Enterotoxins | 2 | 2007 | 12 | 0.140 |
Why?
| | Aromatase Inhibitors | 2 | 2007 | 15 | 0.140 |
Why?
| | Pregnancy | 1 | 2023 | 2620 | 0.140 |
Why?
| | Kallikreins | 2 | 2006 | 22 | 0.140 |
Why?
| | Nitriles | 2 | 2007 | 69 | 0.140 |
Why?
| | Triazoles | 2 | 2007 | 120 | 0.130 |
Why?
| | Receptor, erbB-2 | 2 | 2005 | 79 | 0.130 |
Why?
| | Mice | 4 | 2014 | 6413 | 0.130 |
Why?
| | Lethal Dose 50 | 1 | 2014 | 21 | 0.130 |
Why?
| | Medical Oncology | 2 | 2006 | 102 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2014 | 17 | 0.120 |
Why?
| | Neoplasms | 1 | 2005 | 1316 | 0.120 |
Why?
| | Ascites | 1 | 2014 | 28 | 0.120 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 194 | 0.120 |
Why?
| | Hematopoiesis | 1 | 2014 | 80 | 0.120 |
Why?
| | Safety | 1 | 2014 | 92 | 0.120 |
Why?
| | Stomach | 1 | 2014 | 80 | 0.120 |
Why?
| | Survival Analysis | 2 | 2013 | 735 | 0.120 |
Why?
| | Spectrometry, Fluorescence | 1 | 2013 | 53 | 0.110 |
Why?
| | Carcinoma, Endometrioid | 2 | 2010 | 41 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 180 | 0.110 |
Why?
| | Incidence | 1 | 2016 | 1082 | 0.110 |
Why?
| | Administration, Oral | 1 | 2013 | 459 | 0.110 |
Why?
| | Papillomaviridae | 3 | 2013 | 107 | 0.100 |
Why?
| | Animals | 5 | 2014 | 14385 | 0.100 |
Why?
| | Cytokines | 1 | 2014 | 676 | 0.090 |
Why?
| | Cerclage, Cervical | 1 | 2009 | 7 | 0.090 |
Why?
| | Arkansas | 1 | 2016 | 2100 | 0.090 |
Why?
| | Estrogens | 1 | 2011 | 244 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2011 | 5604 | 0.090 |
Why?
| | Genes, erbB-2 | 2 | 2005 | 8 | 0.080 |
Why?
| | Gene Amplification | 2 | 2005 | 57 | 0.080 |
Why?
| | Carcinoma, Papillary | 2 | 2005 | 65 | 0.080 |
Why?
| | Male | 4 | 2014 | 27334 | 0.080 |
Why?
| | Leiomyosarcoma | 1 | 2007 | 25 | 0.080 |
Why?
| | Clostridium perfringens | 1 | 2007 | 6 | 0.080 |
Why?
| | Carcinosarcoma | 1 | 2007 | 18 | 0.080 |
Why?
| | Intestinal Diseases | 1 | 2007 | 36 | 0.080 |
Why?
| | Melanoma | 1 | 2011 | 313 | 0.080 |
Why?
| | Membrane Proteins | 2 | 2007 | 389 | 0.080 |
Why?
| | Radiation Injuries, Experimental | 1 | 2007 | 105 | 0.070 |
Why?
| | Endometrium | 2 | 2020 | 43 | 0.070 |
Why?
| | Infertility, Female | 1 | 2006 | 21 | 0.070 |
Why?
| | Oncogene Proteins, Viral | 1 | 2005 | 57 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 117 | 0.070 |
Why?
| | Dysgerminoma | 1 | 2004 | 3 | 0.070 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2004 | 6 | 0.060 |
Why?
| | Retroperitoneal Space | 1 | 2004 | 24 | 0.060 |
Why?
| | Immunotherapy, Adoptive | 1 | 2005 | 134 | 0.060 |
Why?
| | Patient Selection | 1 | 2006 | 286 | 0.060 |
Why?
| | Gynecology | 1 | 2004 | 50 | 0.060 |
Why?
| | Interleukin-6 | 1 | 2005 | 315 | 0.060 |
Why?
| | Lymphatic Metastasis | 1 | 2004 | 256 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 426 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2007 | 1089 | 0.050 |
Why?
| | Adolescent | 4 | 2013 | 6897 | 0.050 |
Why?
| | Immunotherapy | 1 | 2005 | 263 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 462 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 562 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2014 | 1737 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2004 | 225 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2007 | 642 | 0.050 |
Why?
| | Preoperative Period | 1 | 2020 | 59 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 57 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 61 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1138 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 95 | 0.040 |
Why?
| | Cell Line, Tumor | 3 | 2007 | 1550 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 808 | 0.040 |
Why?
| | Claudin-3 | 2 | 2007 | 5 | 0.040 |
Why?
| | Claudin-4 | 2 | 2007 | 7 | 0.040 |
Why?
| | Mice, SCID | 2 | 2007 | 196 | 0.030 |
Why?
| | Lymphocyte Activation | 2 | 2007 | 197 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 314 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 278 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2014 | 160 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 99 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 95 | 0.030 |
Why?
| | Apoptosis | 1 | 2020 | 1300 | 0.030 |
Why?
| | Optics and Photonics | 1 | 2013 | 13 | 0.030 |
Why?
| | Combined Modality Therapy | 2 | 2007 | 692 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2005 | 309 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2014 | 170 | 0.030 |
Why?
| | Spectrum Analysis | 1 | 2013 | 79 | 0.030 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2013 | 51 | 0.030 |
Why?
| | Prospective Studies | 2 | 2013 | 2604 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 162 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2005 | 1202 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 163 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 129 | 0.020 |
Why?
| | Prognosis | 2 | 2005 | 2118 | 0.020 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 15 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 94 | 0.020 |
Why?
| | Mast Cells | 1 | 2007 | 64 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.020 |
Why?
| | Remission Induction | 1 | 2007 | 221 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 158 | 0.020 |
Why?
| | Lymphocytes | 1 | 2007 | 168 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 2005 | 21 | 0.020 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2005 | 33 | 0.020 |
Why?
| | Sampling Studies | 1 | 2005 | 40 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 259 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2007 | 569 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2005 | 58 | 0.020 |
Why?
| | Paraffin Embedding | 1 | 2005 | 56 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2005 | 59 | 0.020 |
Why?
| | Probability | 1 | 2005 | 176 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 240 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 232 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2006 | 398 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 195 | 0.020 |
Why?
| | Carboplatin | 1 | 2004 | 62 | 0.020 |
Why?
| | Etoposide | 1 | 2004 | 85 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2005 | 219 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2005 | 176 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2004 | 119 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 130 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2005 | 477 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2007 | 546 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2005 | 531 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2005 | 431 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 673 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 1663 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 474 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 4318 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 923 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2005 | 373 | 0.010 |
Why?
| | Clinical Competence | 1 | 2006 | 446 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2006 | 1228 | 0.010 |
Why?
| | Survival Rate | 1 | 2005 | 951 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2003 | 485 | 0.010 |
Why?
| | Regression Analysis | 1 | 2003 | 445 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 1198 | 0.010 |
Why?
| | Rats | 1 | 2007 | 3415 | 0.010 |
Why?
| | Risk Assessment | 1 | 2005 | 1361 | 0.010 |
Why?
| | Child | 1 | 2004 | 7341 | 0.010 |
Why?
|
|
Burnett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|